-$0.19 Earnings Per Share Expected for Mesoblast limited (MESO) This Quarter

Brokerages predict that Mesoblast limited (NASDAQ:MESO) will announce earnings of ($0.19) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Mesoblast’s earnings. The lowest EPS estimate is ($0.23) and the highest is ($0.15). Mesoblast posted earnings per share of ($0.10) in the same quarter last year, which would indicate a negative year-over-year growth rate of 90%. The company is scheduled to report its next quarterly earnings results on Tuesday, February 26th.

On average, analysts expect that Mesoblast will report full-year earnings of ($0.93) per share for the current year, with EPS estimates ranging from ($1.03) to ($0.85). For the next fiscal year, analysts forecast that the business will report earnings of ($0.83) per share, with EPS estimates ranging from ($1.00) to ($0.65). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Mesoblast.

Mesoblast (NASDAQ:MESO) last issued its quarterly earnings results on Thursday, November 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.04. The firm had revenue of $11.64 million for the quarter, compared to the consensus estimate of $1.03 million. Mesoblast had a negative net margin of 171.79% and a negative return on equity of 12.90%.

A number of research analysts have recently issued reports on MESO shares. TheStreet downgraded shares of Mesoblast from a “c-” rating to a “d+” rating in a research report on Monday, December 10th. Zacks Investment Research downgraded shares of Mesoblast from a “buy” rating to a “hold” rating in a research report on Wednesday, October 31st. Oppenheimer set a $15.00 price target on shares of Mesoblast and gave the stock a “buy” rating in a research report on Thursday, December 13th. Maxim Group restated a “buy” rating and issued a $16.00 price target on shares of Mesoblast in a research report on Monday, November 12th. Finally, Cantor Fitzgerald set a $23.00 price target on shares of Mesoblast and gave the stock a “buy” rating in a research report on Sunday, November 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $11.92.

Several institutional investors have recently added to or reduced their stakes in MESO. Capital World Investors acquired a new position in shares of Mesoblast during the 3rd quarter valued at $3,695,000. Renaissance Technologies LLC lifted its position in shares of Mesoblast by 249.8% during the 3rd quarter. Renaissance Technologies LLC now owns 165,161 shares of the company’s stock valued at $1,348,000 after acquiring an additional 117,951 shares during the period. Citadel Advisors LLC acquired a new position in shares of Mesoblast during the 3rd quarter valued at $215,000. Jane Street Group LLC acquired a new position in shares of Mesoblast during the 3rd quarter valued at $117,000. Finally, Penbrook Management LLC lifted its position in shares of Mesoblast by 6.2% during the 4th quarter. Penbrook Management LLC now owns 240,900 shares of the company’s stock valued at $993,000 after acquiring an additional 14,000 shares during the period. Institutional investors own 3.01% of the company’s stock.

Shares of NASDAQ MESO traded up $0.04 during midday trading on Monday, reaching $4.31. The stock had a trading volume of 37,970 shares, compared to its average volume of 36,903. The company has a market capitalization of $402.11 million, a P/E ratio of -6.84 and a beta of 1.74. Mesoblast has a twelve month low of $3.35 and a twelve month high of $8.78. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.57 and a current ratio of 3.57.

About Mesoblast

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

Further Reading: Quick Ratio

Get a free copy of the Zacks research report on Mesoblast (MESO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply